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ARTICLE
Deubiquitinase Usp12 functions noncatalytically
to induce autophagy and confer neuroprotection
in models of Huntington’s disease
Rebecca Aron1,2,10, Pasquale Pellegrini1, Edward W. Green3,4, Daniel C. Maddison3, Kwadwo Opoku-Nsiah5,
Jinny S. Wong1, Aaron C. Daub1, Flaviano Giorgini3 & Steven Finkbeiner1,2,6,7,8,9
Huntington’s disease is a progressive neurodegenerative disorder caused by polyglutamine-
expanded mutant huntingtin (mHTT). Here, we show that the deubiquitinase Usp12 rescues
mHTT-mediated neurodegeneration in Huntington’s disease rodent and patient-derived
human neurons, and in Drosophila. The neuroprotective role of Usp12 may be specific
amongst related deubiquitinases, as the closely related homolog Usp46 does not suppress
mHTT-mediated toxicity. Mechanistically, we identify Usp12 as a potent inducer of neuronal
autophagy. Usp12 overexpression accelerates autophagic flux and induces an approximately
sixfold increase in autophagic structures as determined by ultrastructural analyses, while
suppression of endogenous Usp12 slows autophagy. Surprisingly, the catalytic activity of
Usp12 is not required to protect against neurodegeneration or induce autophagy. These
findings identify the deubiquitinase Usp12 as a regulator of neuronal proteostasis and mHTT-
mediated neurodegeneration.
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Several neurodegenerative disorders, such as Huntington’sdisease (HD), are characterized by abnormal accumulationof toxic protein species and result in a number of deleter-
ious effects, including dysregulation of protein homeostasis1,2. No
disease-modifying therapies are available for any neurodegen-
erative disease, and as their incidence is rising rapidly in aging
populations throughout the world, identifying potential ther-
apeutic targets is of critical importance.
Although HD is known to be caused by an abnormal expansion
of CAG trinucleotide repeats in the huntingtin (HTT) gene,
phenotypic variation in HD patients with the same HTT muta-
tion suggests that additional factors, both genetic and environ-
mental, influence disease severity and age of onset3. Unbiased
genetic approaches in a number of model systems have identified
potential genetic modifiers of mutant HTT (mHTT) toxicity, but
their pathogenic significance and potential as therapeutic targets
remain largely unexplored4–11.
mHTT is subject to post-translational modifications, such as
ubiquitination and phosphorylation12,13, which have important
implications for its processing, stability, and localization,
that subsequently influence its effect on cellular toxicity. Given the
potential role of ubiquitin signaling and protein homeostasis in
HD pathobiology, we sought to identify genetic modifiers of HD
that are involved in these pathways. We investigated the human
ortholog of a potential genetic modifier originally identified in a
yeast genome-wide screen for loss-of-function enhancers of
mHTT-mediated toxicity, the deubiquitinase UBP134.
Usp12, the eukaryotic ortholog of UBP13, belongs to the
ubiquitin-specific protease (USP) family of deubiquitinases that
are critical for ubiquitin signaling and protein quality control.
USPs function as cysteine proteases to trim or remove ubiquitin
conjugates from selected substrates. Deubiquitination is impor-
tant for ubiquitin signaling-mediated processes, such as regula-
tion of protein levels or activity. Similar to other USP family
members, Usp12 contains the conserved catalytic cysteine/histi-
dine domains and, so far, has only been identified as a deubi-
quitinase for the histones H2A/H2B, Notch, PH domain leucine-
rich repeat protein phosphatase 1, and androgen receptor14. USPs
are emerging as potential therapeutic targets for a number of
human disorders in which ubiquitin-protein homeostasis path-
ways are disrupted, particularly cancers15–17. Due to their
abundance and activity in the nervous system, USPs may also
represent an emerging class of therapeutic targets for
neurodegeneration18.
Here, we demonstrate that Usp12 modifies mHTT-mediated
toxicity in primary rodent and human patient-induced pluripotent
stem cell (iPSC)-derived neurons and in vivo in a Drosophila model
of HD. We find that Usp12 does not require its catalytic activity for
this neuroprotective effect. Moreover, we reveal a non-catalytic
function of Usp12 as a regulator of the cellular degradation path-
way, autophagy. Autophagy induction in primary neurons and
other HD models protects against HD-mediated neurotoxicity19,20.
We propose a mechanism by which Usp12 suppresses HD-related
neurodegeneration via induction of autophagy. Our findings iden-
tify ubiquitin-independent functions of Usp12 that establish it as a
critical regulator of neuronal proteostasis.
Results
Usp12 modulates mHTT toxicity in primary neurons and flies.
We first examined the ability of Usp12 to modify mHTT toxicity
in rodent primary neuron models of HD. For these studies, we
used a physiologically expressed fragment of HTT, N586, which
contains the first 586 amino acids of HTT, to model HD
toxicity21,22. Our model uses a non-pathogenic form of HTT with
a 17-polyglutamine-repeat expansion (Q17), or a pathogenic
form with a 138-polyglutamine-repeat expansion (Q138) that is
toxic to neurons. We previously described a very sensitive method
to longitudinally monitor neurotoxicity in individual neurons by
robotic microscopy and analysis programs23. This technique,
coupled with statistical methods such as Cox proportional
hazards analysis, allows us to track the survival of neurons and to
determine the contribution of different variables to neuronal
survival, such as expression level, localization, and aggregation of
toxic or modifier proteins23. We used this system to monitor the
effect of genetic depletion or overexpression of Usp12 on the
survival of neurons expressing mHTT.
As the Usp12 ortholog was identified as a knockout enhancer
of mHTT in the yeast HD model, we sought to determine if
Usp12 was also a loss-of-function enhancer in our primary
neuronal cell model of HD with the survival assay described
above. Rat primary neurons were co-transfected with green
fluorescent protein (GFP)-tagged HTT-N586Q17 or -N586Q138
and non-targeting short hairpin RNA (nt-shRNA) or shRNA
targeting endogenous rat Usp12 (Usp12-shRNAr) (r designates
rat-specific targeting sequence), and a red fluorescent protein
(RFP) expression construct. The Usp12-shRNAr targeting con-
struct was validated in rat cell lines—PC12 cells and C6 cells, and
in rat primary neurons; Usp12 levels were determined to be
reduced by ~30% at both mRNA and protein levels (Supplemen-
tary Fig. 1a-c). RFP expression was used in this assay as a survival
marker: the loss of RFP fluorescence or the loss of distinctive
neuronal morphology and the disruption of plasma membrane
were used as an indicator of cell death23.
Neurons transfected with these constructs were tracked at a
single-cell level by robotic microscopy at approximately 24-h
intervals for the indicated times (Fig. 1a). Neuronal cell survival
for each cohort was analyzed by Cox proportional hazards
modeling to determine the effect of Usp12 knockdown on mHTT
toxicity. Neurons expressing mHTT-N586Q138 had a greater risk
of death than neurons expressing the nonpathogenic form, HTT-
N586Q17, indicating polyglutamine expansion-dependent toxicity
(Fig. 1b, Table 1). Usp12-shRNAr significantly exacerbated the
risk of death of neurons expressing toxic mHTT-N586Q138
relative to a nt-shRNA (Fig. 1b, Table 1). These results identify
Usp12 as a loss-of-function enhancer of mHTT-mediated toxicity
in primary neurons, indicating that the genetic relationship
between mHTT toxicity and the Usp12 ortholog is conserved
from yeast to mammals, and more importantly, in an HD
relevant cell type, neurons.
The exacerbation of mHTT-mediated toxicity by Usp12
depletion in neurons suggests that endogenous Usp12 has a
protective role in pathways associated with mHTT toxicity. To
determine if upregulating Usp12 is neuroprotective against
mHTT-mediated toxicity, we overexpressed Usp12 in primary
neurons expressing the mHTT constructs as above. Overexpres-
sing human Usp12 by 2.5-fold reduced the risk of death
associated with mHTT-N586Q138 (Fig. 1c, Supplementary Fig. 1c,
Table 1) but did not affect the survival of neurons expressing
HTT-N586Q17. Thus, Usp12 does not promote neuronal viability
generally but protects neurons specifically against HTT-induced
polyglutamine expansion-dependent toxicity. These results sug-
gest that Usp12 is a potent and dose-dependent modulator of
mHTT-dependent neurodegeneration. The specificity of Usp12
effects on mHTT-mediated toxicity was further confirmed with
an siRNA that targets endogenous rat Usp12 at a distinct mRNA
sequence compared to the shRNA described above (Supplemen-
tary Fig. 1d). Human Usp12 overexpressed in our studies is
resistant to knockdown by Usp12-shRNAr and -siRNAr (Supple-
mentary Fig. 1e). Usp12 knockdown with Usp12-siRNAr did not
affect HTT-N586Q17 survival (Fig. 1d, Supplementary Table 1)
but increased mHTT-N586Q138 toxicity (Fig. 1e, Supplementary
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Table 2). The specificity of the increased toxicity observed upon
Usp12 knockdown was confirmed by overexpressing human
Usp12 in neurons. Usp12 rescued the toxicity mediated by the
Usp12-siRNAr (Fig. 1e, Supplementary Table 2).
We next sought to further establish the physiological relevance
of Usp12 as a modifier of mHTT using human neurons from HD
patients that express full-length mHTT under its endogenous
promoter. Neurons differentiated from HD patient-derived iPSCs
exhibit several features reminiscent of HD pathobiology, such as
changes in gene/protein expression, the cytoskeleton, adhesion,
electrophysiological properties, energy metabolism, and survi-
val24. For this assay, we differentiated neuronal cells from an HD
patient with 109 polyglutamine repeats (HDQ109) and an
unaffected individual with 20 polyglutamine repeats (control).
Usp12 overexpression significantly decreased the risk of death of
HDQ109 neurons, but did not affect the survival of control
neurons (Fig. 1f, Supplementary Table 3).
To assess the physiological relevance of our findings from cell
models in an in vivo system, we examined the effect of Usp12 on
neurodegeneration in an extensively used Drosophila model of
HD25. Expression of an expanded polyglutamine exon 1 fragment
(mHTT-ex1Q93) in Drosophila leads to progressive loss of
photoreceptor neurons25, as well as other disease-relevant
phenotypes. Using this feature of HD model flies to monitor
neurodegeneration, we determined the effect of Usp12 knock-
down or Usp12 overexpression on the progressive loss of
photoreceptor neurons (Fig. 1g, Supplementary Fig. 1f). Usp12
knockdown significantly increased, and Usp12 overexpression
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Fig. 1 Usp12 is a modifier of mHTT toxicity in vitro and in vivo. a Representative images of primary neurons expressing RFP captured at the indicated time
intervals after transfection. Expression of RFP is used as a morphological marker to track the survival of neurons by a robotic microscope. Examples of
neurons that survived the entire time course of observation (empty arrowhead) or died by 46 h post transfection (filled arrowhead) are shown (scale bar
= 20 µm). b–e Cumulative risk of death plots of primary rodent cortical neurons. The cumulative risk of neuron death is plotted against time (h) for each
group of neurons transfected with the indicated plasmids. Cox proportional hazards analysis was used to estimate the relative risk of death or hazard ratio
(HR), and the p value was determined with the log rank test (*p < 0.05, **p < 0.01, ***p < 0.001, n.s. not significant) (for statistical information, see
Supplementary Tables 1, 2, and 3). f Survival analysis of human neurons differentiated from patient-derived iPSCs (unaffected individual, control; HD
patient, HDQ109) transfected with MAP2-RFP (morphology marker), and Usp12 or control vectors (statistical information is summarized in Supplementary
Table 3). g Quantification of average rhabdomeres per ommatidium at day 1 and day 7 after eclosion. Two-way ANOVA: genotype effects, p < 0.0001;
age effects, p < 0.0001, n= 8–10 flies per genotype. Multiple comparisons analysis: day 1 genotype analysis for control vs. Usp12 knockdown (p= 0.7020)
and control vs. Usp12 overexpression (p= 0.3589); day 7 genotype analysis for control vs. Usp12 knockdown (p= 0.0041) and control vs. Usp12
overexpression (p= 0.0270). n.s. not significant; *p < 0.05; **p < 0.01. Two-way ANOVA with Bonferroni’s multiple comparisons post hoc test. Error bars
represent s.e.m.
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decreased, mHTT-associated loss of photoreceptor neurons and
neurodegeneration. As ubiquitous or pan-neuronal knockdown of
Drosophila Usp12 results in no identifiable phenotypes26, the
exacerbated loss of photoreceptor neurons in the HD transgenic
flies can be attributed to a specific effect of Usp12 on mHTT-
associated neurodegeneration, rather than an adverse effect of
Usp12 loss of function in neuronal cells.
Usp12 is a specific modifier of mHTT toxicity. Identification of
Usp12 as a modifier of HD suggested that Usp12 could rescue
neurodegeneration in related disorders, such as amyotrophic
lateral sclerosis (ALS) and Parkinson’s disease (PD) that are
characterized by proteotoxic stress. Like HD, these neurodegen-
erative diseases feature accumulations of toxic misfolded proteins
and the appearance of ubiquitin-positive neuronal inclusions.
We tested the effect of Usp12 on neuronal cell survival in
primary neuron models of ALS and PD. The toxic neurodegen-
erative disease-associated proteins, TDP-43, an ALS-causing
mutant of TDP-43, TDP-43A315T, and α-synuclein show overt
toxicity and lead to neuron death when overexpressed in primary
neurons27,28. To determine if Usp12 could modify toxicity of
these disease proteins, we tracked the survival of neurons co-
transfected with Usp12 and either TDP-43 wild type (WT), TDP-
43A315T, or α-synuclein expression constructs. In agreement with
previous results, overexpression of TDP-43 and α-synuclein in
primary neurons significantly increased risk of death (Fig. 2a–c,
Supplementary Table 4). Co-expression with Usp12 did not
reduce the risk of neuron death in the TDP-43 or the α-synuclein
disease models (Fig. 2, Supplementary Table 4) as it did in our
mHTT models (Fig. 1), indicating that Usp12 is not suppressing
neurotoxicity generically.
Usp46 does not rescue mHTT-mediated neuronal death. To
better understand the potential specificity of Usp12 in HD
pathobiology, we compared the effects of Usp12 on mHTT-
mediated toxicity with those of similar related enzymes of the
USP family. The most closely related human homolog to Usp12
is Usp46 (93% protein sequence similarity, with identical active-
site domain sequences; Fig. 3a). Using the robotic microscopy
survival assay described above, we tracked the survival of neu-
rons overexpressing Usp46 and mHTT. When transfected at a
similar gene dose as that at which Usp12 rescues mHTT
toxicity (Fig. 3b), Usp46 did not block degeneration of mHTT-
expressing neurons (Fig. 3c, e, Supplementary Table 5). How-
ever, Usp46 overexpression appeared to increase the risk of
death in neurons co-transfected with a non-pathogenic form of
HTT, HTT-N586Q17 (Fig. 3d, Supplementary Table 5). This
effect depended on the active-site cysteine, C44, as over-
expression of Usp46-C44S did not increase death in cells
expressing HTT-N586Q17 (Fig. 3d). Usp46-C44S did not reduce
the toxicity of mHTT-N586Q138, indicating that the toxicity
seen here with mHTT depends specifically on expression of
mHTT-N586Q138 (Fig. 3e). To demonstrate that the reduction
in toxicity in neurons expressing Usp46-C44S was not due to the
C44S mutation effecting protein expression or stability, we
tested the expression of Usp46 and Usp46-C44S in PC12 cells.
The Usp46-C44S construct produces protein as efficiently and
stably as the WT Usp46 construct (Fig. 3g). No overt toxicity
was observed when equivalent amounts of Usp12 plasmid were
transfected into control neurons (Fig. 3f). Thus, despite the
similarity in protein sequence and conservation of active sites of
Usp12 and Usp46, they have unique neurobiological functions.
These results further suggest that Usp12 has a function distinct
from related USPs, in suppressing mHTT-mediated toxicity.
Catalytically inactive Usp12 suppresses mHTT toxicity. The
inability of Usp46 to suppress mHTT neurotoxicity, despite
having identical catalytic domain sequences to Usp12, suggested
that functional specificity for either of these enzymes resides
outside of these domains, and that catalytic activity was not
required for this function of Usp12. Therefore, we tested the effect
of modulating Usp12 deubiquitinase activity on mHTT toxicity.
Usp12 contains a conserved active-site cysteine residue (C48)
(Fig. 4a). C48 is required for Usp12 deubiquitinating activity
in vitro, as Usp12 with a replacement of this residue by serine
(Usp12-C48S) lacks enzymatic activity29. To test the requirement
of Usp12 deubiquitinating activity in modulating mHTT toxicity,
we examined the effect of Usp12-C48S on mHTT toxicity in our
robotic microscopy survival assay. Despite the mutation, Usp12-
C48S retained the ability to rescue mHTT-mediated toxicity in
primary neurons, indicating that an active-site cysteine is not
required for rescue of mHTT toxicity (Fig. 4b, Table 2).
In order to rule out the possibility that residual protease
activity in the context of the cellular environment contributes to
Table 1 Cox proportional hazards analysis of the effects of Usp12 knockdown or overexpression on survival of rodent primary
neurons
HR 95% CI P value n
Usp12 knockdown
HTT-N568Q17+ nt-shRNA Reference – – 222
HTT-N568Q17+Usp12-shRNAr 0.94 0.69–1.27 0.67050 141
mHTT-N586Q138+ nt-shRNA 1.58 1.23–2.05 0.00042 207
mHTT-N586Q138+Usp12-shRNAr 2.00 1.56–2.57 4.27e-08 209
Usp12 overexpression
HTT-N568Q17+ control vector Reference – – 196
HTT-N568Q17+Usp12 1.41 0.98–2.03 0.06154 190
mHTT-N586Q138+ control vector 2.27 1.63–3.18 1.47e-06 199
mHTT-N586Q138+Usp12 1.64 1.15–2.34 0.00604 189
HTT-N568Q17+ control vector 0.44 0.31–0.61 1.47e-06 196
HTT-N568Q17+Usp12 0.62 0.45–0.84 0.00229 190
mHTT-N586Q138+ control vector Reference – – 199
mHTT-N586Q138+Usp12 0.72 0.53–0.97 0.03165 189
Reference= reference group for statistical analysis
HR hazard ratio, n number of neurons, CI confidence interval
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Usp12 suppression of mHTT-mediated toxicity, we mutated C50,
a cysteine residue adjacent to C48, to serine and determined if it
affected the ability of Usp12 to suppress mHTT toxicity. Usp12-
C50S and Usp12 with both C48S and C50S mutations (Usp12-
DBLCS) suppressed mHTT toxicity as efficiently as WT Usp12
and Usp12-C48S (Fig. 4c, Table 2). Similar to WT Usp12, the
overexpression of Usp12-C48S rescued the toxicity of Usp12
knockdown (Supplementary Fig. 2a, b, Supplementary Table 2).
Expression and stability of WT Usp12 and mutants were
comparable when overproduced in human embryonic kidney
(HEK) cells (Fig. 4d). These results suggest that Usp12 does not
require C48 for its function in suppressing mHTT toxicity and,
furthermore, that an adjacent cysteine residue does not
compensate for the loss of C48 to suppress mHTT toxicity. If
the deubiquitinating activity of Usp12 is not required for its
ability to mitigate mHTT toxicity, we would predict that Wdr20
and Wdr48, two essential co-factors of Usp1229,30, would also not
be required for Usp12-mediated neuroprotection (Fig. 4e).
Indeed, we found that Usp12-C48S reduces mHTT toxicity
despite the knockdown of Wdr48 and/or Wdr20 (Fig. 4f, g,
Supplementary Table 6).
To determine if the catalytic activity of Usp12 was dispensable
for neuroprotection against mHTT toxicity in human neurons,
we tested the effect of Usp12-C48S on survival of an HD patient
line with 53 polyglutamine repeats (HDQ53)31. The HDQ53 line
showed developmental alterations and higher risk of death than
control lines31. Similar to results with the HDQ109 line,
Usp12 significantly increased survival in HD53Q differentiated
neurons to the level of control neuron survival (Figs. 1f and 4h,
Table 3). Usp12-C48S showed a similar level of neuroprotection
in HD53Q neurons, while not affecting survival of the control line
(28 polyglutamine repeats; Fig. 4h, Table 3). As the conversion of
an active-site cysteine to serine could result in generating an
active serine protease32, we also tested the effect of mutating the
active-site cysteine to a less-conserved residue, alanine. Usp12-
C48A rescued mHTT toxicity in our neuron model in a manner
similar to Usp12-C48S (Supplementary Fig. 3).
Our results indicate that an active-site cysteine is not required
for Usp12 function in neuroprotection, and Usp46, despite
containing an identical catalytic domain sequence, does not
rescue mHTT-mediated toxicity. These findings further support
the concept that Usp12 functions by modulating mHTT-
mediated neurotoxicity in a non-canonical manner.
Usp12 does not affect inclusion body dynamics. We next
explored potential ubiquitin-independent mechanisms by which
Usp12 might modulate mHTT toxicity. Controlling for other
variables, the accumulation of mHTT increases, and mHTT
inclusion body (IB) formation decreases the risk of neuronal
death23. Possible mechanisms by which Usp12 could function are
by modulating mHTT levels, aggregation, or IB dynamics in a
ubiquitin-independent manner.
To examine the effect of Usp12 on mHTT turnover, we
measured the half-life of mHTT proteins fused to the photo-
convertible protein, mEos2, in our primary neuron model with an
optical pulse-labeling assay. This approach is more suitable and
sensitive than conventional metabolic pulse chase assays to
measure the clearance of toxic, aggregation-prone proteins33,34.
mEos2 fluoresces green, but when pulsed with 405 nm wave-
length, the existing protein population is photoconverted to a red
fluorescent form. The half-life of mHTT-mEos2 can be
determined by measuring the decay of the photoconverted red
form over time. Half-life of soluble mHTT protein was
determined by analyzing the decay rate of only visibly diffuse
mHTT protein. Neither Usp12 nor Usp12-C48S significantly
modified either the mean half-life or distribution of half-lives of
soluble mHTT (Supplementary Fig. 4).
To visualize potential co-localization of Usp12 with mHTT in
neurons, we utilized GFP- or RFP-tagged versions of Usp12.
Fluorescent protein-tagged Usp12 retains its function in suppres-
sing mHTT toxicity in primary neurons, and therefore represents
a functional version of Usp12 suitable for our studies here
(Supplementary Fig. 5). We observed that both RFP-Usp12-WT
and -C48S localize to mHTT-N586Q138-GFP inclusions in
primary neurons (Fig. 5a).We next used Cox proportional
hazards analysis to determine the influence of Usp12 on the risk
factors for mHTT-mediated toxicity, expression levels, and IB
formation. Usp12 and Usp12-C48S did not affect these risk
factors for mHTT-mediated toxicity (Supplementary Table 7).
We also tested the effect of Usp12 or Usp12-C48S on the risk of
IB formation, which if increased, could indicate a protective
mechanism of Usp12. Our analysis indicated that neither Usp12
nor Usp12-C48S affects the risk of mHTT IB formation
(Supplementary Fig. 6, Supplementary Table 8).
Usp12 regulates autophagy in primary neurons. Usp12 did not
seem to influence mHTT levels, the propensity of neurons to
form mHTT IBs, or the contribution of risk factors to mHTT-
mediated toxicity and neuronal survival. Thus, we searched for an
alternative connection between Usp12 and mHTT. Using the
available association data for Usp12 and mHTT interactions, we
mapped a protein–protein interaction network between Usp12
and mHTT, and identified the autophagy receptor Optineurin
(Optn) as a potential link (Fig. 5b, Supplementary Fig. 7). A
physical interaction between Optn and mHTT has been reported,
and Optn interacts with Wdr20, a cofactor that directly interacts
with Usp1214,35–38. Inhibition of autophagy results in the
accumulation of autophagy receptors in punctate structures.
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Fig. 2 Usp12 overexpression is not a generic suppressor of neurotoxicity. a–c Cumulative risk of death plots for primary neurons co-transfected with
control, TDP-43 (a), TDP-43A315T (b), α-synuclein (c), and Usp12 or empty vector control plasmids. Cox proportional hazards analysis was used to
estimate the relative risk of death, or hazard ratio (HR), and the p value was determined with the log rank test (***p < 0.001) (Supplementary Table 4)
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Upon inhibiting autophagy with ammonium chloride or bafilo-
mycin A, Usp12 and Usp12-C48S co-localized with Optn in
punctate structures throughout the cell (Fig. 5c, Supplementary
Fig. 8a). About 60% and 40% of the Usp12 and Usp12-C48S
puncta, respectively, co-localized with Optn (Supplementary
Fig. 8c). Co-immunoprecipitation confirmed an interaction
between Usp12 or Usp12-C48S and Optn (Fig. 5e).
To further validate the interaction of Usp12 with autophagy
receptors, we examined the autophagy receptor p62, finding that
both Usp12 and Usp12-C48S co-localized with p62 in punctate
structures when autophagy was inhibited (Fig. 5d, Supplementary
Fig. 8b), an observation that was confirmed by super-resolution
microscopy (Supplementary Fig. 9a, b). Usp12 (80%) and Usp12-
C48S (50%) puncta co-localized with p62 (Supplementary
Fig. 8d). An interaction between Usp12 or Usp12-C48S and
p62 was also confirmed by co-immunoprecipitation (Fig. 5f). To
investigate the interaction of Usp12 with endogenous autophagic
receptors, we observed RFP-Usp12-expressing neurons labeled
with p62 antibodies using super-resolution microscopy. Similar to
previous data, we observed a subset of p62 and Optn puncta co-
localized with Usp12 (Supplementary Fig. 9a, b).
To investigate a potential function of Usp12 in modulating
autophagy, we used an optical pulse-labeling assay to determine
the effect of overexpressing or depleting Usp12 on the half-life of
a cb
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the autophagy protein LC3 in primary neurons. LC3, a
mammalian homolog of yeast Atg8, incorporates into autophago-
somes, and is selectivity degraded via autophagy39,40. The LC3
half-life reflects autophagic activity and can be used as a sensitive
reporter of autophagic flux39. In our assay, the half-life of LC3
fused to a photoswitchable protein, Dendra2-LC3, is measured in
individual, living neurons by robotic microscopy33,34. Dendra2-
LC3 in the green channel represents both the Dendra2-LC3
existing at the time of photoconversion and the newly synthesized
protein throughout the experiment. Dendra2-LC3 in the
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Table 2 Cox proportional hazards analysis of the effects of Usp12 catalytic domain mutants on neuron survival
HR 95% CI P value n
mHTT-N586Q138+ control vector Reference – – 319
mHTT-N586Q138+Usp12 0.71 0.59–0.86 0.51e-03 294
mHTT-N586Q138+Usp12-C48S 0.61 0.50–0.75 1.74e-06 283
mHTT-N586Q138+Usp12-C50S 0.73 0.60–0.89 0.22e-02 266
mHTT-N586Q138+Usp12-DBLCS 0.58 0.48–0.72 5.84e-08 324
Reference= reference group for statistical analysis
HR hazard ratio, n number of neurons, CI confidence interval
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red channel represents only the population existing at photo-
conversion (Fig. 6a). By following the decay of Dendra2-LC3
fluorescence in the red channel, we can determine the clearance
rate of LC3, without interference from newly synthesized
Dendra2-LC3 protein.
Usp12 and Usp12-C48S overexpression significantly decreased
the mean half-life of LC3, but did not affect the half-life of the
control protein Dendra2 (Fig. 6b, c). Usp12 and Usp12-C48S also
significantly left-shifted the distribution of LC3 half-lives in
individual neurons, but not the control protein Dendra2.
Conversely, Usp12 knockdown increased the mean half-life of
LC3, while also significantly right-shifting the distribution of LC3
half-lives in individual neurons (Fig. 6d). Usp12 knockdown did
not affect half-life of the control protein Dendra2 (Fig. 6e).
We next examined the effects of Usp12 on autophagic
structures in primary neurons by electron microscopy (EM).
Neurons transduced with either Usp12 overexpression lentivirus
or GFP control lentivirus were examined by EM. Neurons
overexpressing Usp12 had approximately sixfold more autopha-
gic structures, such as pre-autophagosomes, autophagosomes,
and autolysosomes, than GFP lentivirus–transduced neurons
(Fig. 6f, Supplementary Fig. 10).
To further confirm that the effect of Usp12 on LC3 turnover
reflects a functional role of Usp12 in autophagy, we tested the
effect of Usp12 on LC3 half-life in the context of genetic depletion
of Atg7. Genetic depletion of Atg7 by shRNA knockdown
increases Dendra2-LC3 half-life in primary neurons in an optical
pulse-labeling assay similar to the one used here33. Consistent
with these results, we showed that Usp12 no longer effects
changes in Dendra2-LC3 half-life in the context of Atg7-shRNA
knockdown (Fig. 7a, b), indicating that Usp12-mediated LC3
turnover in our assay reflects changes specific to an Atg7-
dependent autophagy pathway of LC3 clearance.
Dysregulation of autophagy is linked to a number of
neurodegenerative disorders, including HD41. Usp12 induction
of autophagy is a potential mechanism by which Usp12 confers
neuroprotection in HD models. To investigate the relationship
between Usp12 function in autophagy and neuroprotection, we
tested the ability of Usp12 to modulate mHTT toxicity in neurons
repressed for autophagy by knockdown of Atg7, a regulator of
autophagy. Usp12 nor Usp12-C48S suppressed mHTT-N586Q138
neurotoxicity during Atg7 knockdown (Fig. 7c, Supplementary
Table 9). By contrast, Usp12 or Usp12-C48S suppressed mHTT-
N586Q138-mediated neurotoxicity when co-expressed with non-
targeting-shRNA, indicating that the neuroprotective effects of
Usp12 or Usp12-C48S require a functioning autophagic clearance
pathway (Figs. 7c and 1c). The dependence of Usp12-mediated
neuroprotection on Atg7-dependent autophagy supports our
model, whereby Usp12 modulates mHTT toxicity via its function
in autophagy induction.
Discussion
There are no effective therapies for HD. Studies exploring
potential genetic disease-modifying agents have the potential to
lead to the identification of specific molecular targets, and further
our understanding of relevant molecular pathways for therapeutic
intervention. In our studies, we examined the candidate modifier
Usp12 for its effect on mHTT toxicity. Given the wide debate on
reliable pre-clinical models that recapitulate HD, here we vali-
dated our findings in multiple complementary models to ensure
relevance to human disease. We identified Usp12 as a modifier of
mHTT-associated neurodegeneration in rodent primary neurons,
human HD patient-derived iPSC-differentiated neurons and
in vivo using a Drosophila model of HD. Investigation into the
neuroprotective mechanism of Usp12 revealed that Usp12 is a
component of the autophagic machinery and a regulator of
autophagic flux in neurons.
Initially, we hypothesized that mHTT was a substrate of Usp12
deubiquitinating activity, which could be a potential mechanism
for regulating stability, localization, or other ubiquitin-related
signaling activity of ubiquitin-conjugated mHTT. Interestingly,
we found that Usp12 does not require its deubiquitinating activity
to suppress mHTT neuronal toxicity. Although still thought to be
relatively uncommon, non-canonical functions of other deubi-
quitinases have been reported. The deubiquitinase OTUB1
functions non-catalytically in regulation of DNA repair, and the
Usp14 ortholog in yeast, Ubp6, functions non-catalytically to
delay proteasome-dependent protein degradation42,43. Our stu-
dies identifying non-catalytic functions of Usp12 support the idea
that deubiquitinases may generally function as multimodal pro-
teins. Identification of potential non-catalytic functions of deu-
biquitinases could be of significance regarding effects or
consequences of catalytic site inhibition, which is becoming an
increasingly studied therapeutic strategy44.
The most closely related human homolog of Usp12, Usp46, did
not function in a manner similar to Usp12 in suppressing mHTT
toxicity when transfected into neurons at the same gene dosage.
Expression of Usp46, in contrast to Usp12, is neurotoxic on its
own, as we observed an increased risk of death of neurons
overexpressing Usp46. The toxic effect of Usp46 depended on its
deubiquitinating activity as expression of the catalytically inactive
mutant of Usp46 was not toxic to neurons. These results suggest
that Usp12 and Usp46 have distinct neurobiological functions,
despite sharing >90% amino-acid sequence similarity and iden-
tical catalytic domain sequences. Furthermore, these results sug-
gest that the functional specificity of Usp12 in suppressing mHTT
toxicity is conferred by sequences that reside outside the con-
served catalytic domains, and further support the idea that Usp12
has distinct, non-catalytic functions among related deubiquiti-
nases. Future studies characterizing the regulation of expression,
localization, and activity of these proteins in neuronal cells will
lead to a better understanding of the mechanisms conferring their
functional specificity.
A potential coping mechanism that neurons may utilize in
response to expression of toxic mHTT is the acute formation of
IBs. Indeed, mHTT IB formation is a predictor of neuronal
Table 3 Cox proportional hazards analysis of non-catalytic
Usp12 effect on survival of patient-derived iPSC-
differentiated neurons
HR 95% CI P value n
Control cells+ control
vector
Reference – – 163
Control cells+Usp12 0.84 0.58–1.20 0.339 88
Control cells+Usp12-C48S 0.84 0.55–1.29 0.434 55
HDQ53 cells+ control
vector
1.79 1.39–2.31 6.13e-06 227
HDQ53 cells+Usp12 1.10 0.83–1.46 0.498 180
HDQ53 cells+Usp12-C48S 1.10 0.83–1.47 0.499 161
Control cells+ control
vector
0.56 0.43–0.72 6.13e-06 163
Control cells+Usp12 0.47 0.34–0.65 8.68e-06 88
Control cells+Usp12-C48S 0.47 0.31–0.71 0.000274 55
HDQ53 cells+ control
vector
Reference – – 227
HDQ53 cells+Usp12 0.62 0.48–0.78 9.25e-05 180
HDQ53 cells+Usp12-C48S 0.62 0.48–0.79 0.000172 161
Reference= reference group for statistical analysis
HR hazard ratio, n number of neurons, CI confidence interval
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survival. Neurons that form IBs survive longer, possibly by
sequestering toxic mHTT species into a relatively more inert
state23. We observed that Usp12 co-localizes to mHTT IBs in
primary neurons; however, we saw no effect of Usp12 on the
proportion of cells that formed IBs. Usp12 may be functioning to
alter IB dynamics, such as stability, content, or localization, which
a more in-depth biochemical analysis could reveal. As autophagy
is the primary clearance pathway for mHTT IBs20, the Usp12/
mHTT IB interaction might be directly relevant to the function of
Usp12 that we discovered in modulating autophagy. It is con-
ceivable that Usp12 has additional yet unknown autophagy
substrates or receptors that are necessary for the selective clear-
ance of subspecies of mHTT IBs.
Stimulating the ubiquitin proteasome system (UPS) or autop-
hagic clearance pathways is also a protective coping mechanism
in response to the expression and accumulation of toxic mHTT
protein. mHTT containing a pathogenic polyglutamine length,
such as Q46, is preferentially sensitive to autophagic rather than
UPS-mediated clearance34. We reported development of a sen-
sitive assay for measuring autophagic flux in single neurons by
optical pulse labeling33,34. This assay allows us to measure the
clearance rate of the autophagy substrate LC3. As presented here,
neurons expressing Usp12 cleared LC3 faster than control neu-
rons. Conversely, neurons in which Usp12 expression was
knocked-down cleared LC3 more slowly than control neurons.
Using the clearance rate of LC3 as a sensitive indicator of
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autophagic capacity, we conclude from these studies that Usp12
can function as a modulator of autophagic flux in primary neu-
rons. Since a non-catalytic mutant of Usp12, Usp12-C48S, sti-
mulated LC3 clearance as efficiently as Usp12, we additionally
conclude that this function of Usp12 is independent of its deu-
biquitinating activity.
Interestingly, although these studies indicate endogenous
Usp12 has a role in modulating autophagic flux, genetic knock-
down of Usp12 is not overtly toxic to neurons. The level of
reduction of autophagic flux by Usp12 knockdown under normal
cellular conditions might not be sufficient to induce toxicity or
other components of the autophagic pathway may sufficiently
compensate for the loss of Usp12 function in the pathway under
basal conditions. Under conditions of stress, however, such as
with expression and accumulation of toxic mHTT protein, the
loss of Usp12 function in regulating autophagic flux may con-
tribute to the exacerbation of mHTT-associated neurotoxicity.
Despite the strong effect of Usp12 on autophagy, we did not see
an effect of Usp12 on clearance of mHTT using a similar optical
pulse-labeling assay to measure mHTT half-life. One possible
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explanation is that a subpopulation of HTT conformers may exist
that are especially toxic, and that Usp12 preferentially clears
these. If that subpopulation of mHTT is small relative to the
overall size of the mHTT pool, its clearance by Usp12 would
elude detection with our optical pulse-labeling assay, which
measures effects on all HTT species. Furthermore, if that con-
former is not on the pathway that leads to IB formation, it would
also explain why no effect of Usp12 on IB formation was
observed. Another possibility is that Usp12 stimulation of
autophagy confers neuroprotection primarily by clearing cargo
other than mHTT. In support of this hypothesis, others have
observed that the polyglutamine-expanded proteins can trigger a
collapse in proteostasis that affects the levels of other metastable
proteins1 and have suggested that neurodegeneration may be the
result of a complex loss of function of these other metastable
proteins45. Toxic mHTT protein also interferes with cargo
recognition that is required for efficient autophagy46. In this case,
autophagosomes from HD neurons might inefficiently recognize
and sequester cargo, such as cytosolic organelles and proteins,
which in turn contribute to HD-associated cellular toxicity.
Usp12 stimulation of autophagy, in the context of mHTT, could
lead to more efficient cargo loading in autophagosomes, and
thereby reduce mHTT-associated toxicity.
The specificity of Usp12 in modulating mHTT toxicity, com-
pared to our neuronal models of PD and ALS, is of interest from a
therapeutic perspective. Both α-synuclein and TDP-43 are sub-
strates for autophagic degradation33,47,48, and so, we might predict
that stimulation of autophagy by Usp12 overexpression would also
be neuroprotective in the related PD and ALS neuron models.
However, we observed that Usp12 co-expression did not rescue
neuronal toxicity caused by TDP-43 or α-synuclein expression.
One potential explanation for this finding is that because polyQ-
containing proteins interfere with the Beclin1-induced autophagy
pathway49, Usp12 expression may specifically compensate for
mHTT-related defects in autophagy. Identification of signaling
pathways that regulate Usp12 catalytic and non-catalytic functions
will help to determine how Usp12 may be utilized as a neuro-
protective agent for various disease models in which stimulation of
autophagy could be beneficial. We have found an intriguing
interaction of Usp12 with p62 and Optn, two key receptors
necessary for the selective-autophagic clearance of misfolded
proteins, mitochondria, and protein aggregates. Further studies
will be needed to elucidate the relevance of these interactions for
the selectivity of Usp12 in rescuing mHTT toxicity.
In summary, our studies identify Usp12 as a potent modifier of
mHTT-mediated neurotoxicity, and a non-canonical deubiquitinase,
which regulates autophagic flux in primary neurons. Our studies are
consistent with previous publications indicating that upregulation of
autophagy is neuroprotective in cell and animal models of HD19,20.
Future studies directed toward understanding the precise molecular
function of Usp12 in autophagy and its relationship to neurotoxicity
will help to further establish the therapeutic potential of this genetic
modifier for the treatment of HD.
Methods
Plasmids. Human pGW1-HTT-N586 plasmids were generated by PCR amplifying
the N-terminal 586 amino acids of full-length Q17 or Q138 human huntingtin, and
inserted into pGW1-exon1-Q17-eGFP at KpnI and BamHI restriction sites. HTT-
mEos2 plasmid was generated by replacing the enhanced GFP (eGFP) tag with the
mEos2 sequence. TDP-43- and α-synuclein-bearing plasmids consisted of human
TDP-43 and α-synuclein, respectively. The A315T mutation was created by site-
directed mutagenesis of the adenine base at position 943 to guanine27,28,33. Usp46
cDNA was amplified from HEK293 cell total RNA with primers 5′-TTT TTG GTA
CCA TGA CTG TCC GAA ACA TCG CCT CC ATC-3′ and 5′-TTT TGG ATC
CTT ACT CTC TTG ACT GAT AGA ATA AAA TAT ATC C-3′, and cloned into
pGW1 plasmid at KpnI and BamHI restriction sites. Usp12-C48S, Usp12-C48A,
Usp12-C50S, Usp12-DBLCS, and Usp46-C44S were generated by site-directed
mutagenesis. Dendra2 was cloned into pGW1-CMV from pDendra2-N (Evrogen)
using HindIII and MfeI. pGW1-Dendra2-LC3 was generated by subcloning the
LC3 fragment from pEGFP-LC3 into pGW1-Dendra2 plasmid33,40. shRNA oligos
targeting rat Usp12 5′-TCG AGT ATA TCG ATG AAG CTG GTC CAT TGA TAT
CCG TGG ACC AGC TTC ATC GAT ATA TTT TTT CCA ATT GG-3′), and nt-
shRNA oligos (5′-CTC GAG GTA ATA TAG CAA GGC GAG AAT TCA AGA
GAT TCT CGC CTT GCT ATA TTA CTT TTT TAA GCT T-3′) were cloned into
pSilencer 1.0 or FUGW lentiviral vector.
Cell culture and transfection. Rat cortices were dissected from embryonic day
18–21 rats, digested with papain (10 U/ml) and 0.6 × 106 cells/ml on a poly-lysine/
laminin substrate27,50. Primary neuron cultures were transfected at 4–5 days
in vitro with 50–600 ng plasmid DNA depending on the construct, and 0.5 µl of
Lipofectamine 2000 per well in the 96-well plates. The incubation time of the
Lipofectamine 2000/DNA complexes with the cells is limited to 30–60 min to
prevent toxicity of the transfection to neurons. In general, transfection of primary
neurons by lipofection results in 1–5% transfection efficiency, which sparsely labels
the cultures and facilitates single-cell microscopy studies. HEK293T cells were
maintained in Dulbecco’s modified Eagle medium (DMEM)/10% fetal bovine
serum, and PC12 cells were maintained in DMEM/10% horse serum, 5% fetal
bovine serum. Cell lines were transfected with Lipofectamine 2000 according to the
manufacturer’s protocols (Life Technologies).
Neuronal differentiation of NSCs. Neural stem cells (NSCs) were maintained in
Stemline (Sigma) supplemented with 100 ng/ml epidermal growth factor and
fibroblast growth factor (Chemicon). Briefly, NSCs were differentiated according to
the long protocol, whereby cells were incubated with NIM (DMEM:
F12 supplemented with N2 and B27) for 5 days, followed by supplementation with
25 ng/ml brain-derived neurotrophic factor (BDNF; Peprotech) for 2 days, and
then supplementation for 21 days with BDNF, 10 nM purmorphamine (Santa Cruz
Biotechnology), and 100 ng/ml DKK (R&D), followed by supplementation
with BDNF, 0.5 mM dibutyryl cyclic AMP (Sigma), and 0.5 mM valproic acid
(Sigma)24,31. Transfections were performed with amaxa electroporation, according
to manufacturer instructions at approximately day 28.
Fly stocks. Flies were raised on maize medium, in LD12:12 at 25 °C. The elav-
GAL4 [c155] and actin-GAL4 [3954] drivers were obtained from the Bloomington
Stock Center, Indiana. The w;+;UAS Htt93Q exon 125 flies were a gift from Larry
Marsh and Leslie Thompson (University of California, Irvine). CG7023 RNAi lines
Fig. 6 Usp12 modulates autophagy in neurons. a Representative images of an optical pulse-labeling experiment to measure Dendra2 or Dendra2-LC3 half-
life in living neurons. Dendra2 protein is observed in neurons in the green fluorescence channel before and after 405 nm pulse photoswitch, but Dendra2 in
the red fluorescence channel is only observed after the photoswitching pulse (scale bar= 20 µm). b Left panel, mean half-life of photoconverted Dendra2-
LC3 in Usp12 or Usp12-C48S compared to control. Right panel, density plot showing distribution of Dendra2-LC3 half-lives in individual neurons expressing
empty vector control, Usp12, or Usp12-C48S. c Usp12 or Usp12-C48S does not affect mean control protein Dendra2 half-life (left panel) or half-life
distributions in individual neurons (right panel). d Mean half-life of Dendra2-LC3 (left panel) in Usp12-shRNAr-expressing neurons compared to a non-
targeting (nt) shRNA; (right panel) density plots. e Graphs of mean half-life (left) and density plots (right) of Dendra2 control in nt-shRNA or Usp12-
shRNAr neurons. Number of neurons per group—Dendra2-LC3+: empty vector, n= 121; Usp12, n= 121; Usp12-C48S, n= 81; nt-shRNA, n= 341; Usp12-
shRNAr, n= 328; Dendra2+: empty vector, n= 162; Usp12, n= 210; Usp12-C48S, n= 173; nt-shRNA, n= 160; Usp12-shRNAr, n= 130. p Value for mean
half-life and distributions determined by Mann-Whitney and Kolmogorov-Smirnov tests, respectively (***p < 0.001). f Electron micrographs and
quantification of autophagic structures in neurons transduced with Usp12 or GFP lentivirus. AV autophagic vacuoles, C curving phagophore, M
mitochondria, G Golgi, rER rough endoplasmic reticulum, Ly lysosome, N nucleus. Quantification of autophagic structures represents the average number
of autophagic vacuoles (pre-autophagic, autophagosome, and autolysosome structures) per EM image (×4000 micrograph). GFP, n= 28 images; Usp12,
n= 33 images. Scale bar= 1 µm. Error bars represent s.e.m. (***p < 0.001). Scale bar= 1 µm
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were obtained from the Vienna Drosophila RNAi Center (stock # 108313). The
UAS CG7023 overexpression flies were made by cloning the full-length CG7023
CDS from the BDGP clone RE52890 (Genbank BT010235) into the pJFRC2 vec-
tor51, obtained from Addgene—plasmid # 26214) between the XhoI and XbaI sites.
The resulting plasmid was purified and injected by BestGene Inc into the same attP
insertion site as used by the VDRC (Landing site VIE-260B, VDRC stock # 60100).
An additional control line was created by injecting the pKC26 vector without any
hairpin construct into the VIE0260B background. The knockdown, control, and
overexpression lines were crossed into the w;+;UAS Htt93Q genetic background
using standard techniques, and the resulting flies crossed to the elav-GAL4 driver to
generate the experimental flies.
Pseudopupil analysis. The number of visible rhabdomeres per ommatidium was
scored for 50–100 ommatidia per fly, with 8–10 flies examined per genotype at day
0, 1, or 7 post eclosion. Heads from aged flies were fixed to slides with fingernail
polish, and rhabdomeres were examined at ×500 magnification using an Olympus
BH2 microscope.
Robotic imaging and analysis. For survival analysis, neurons were imaged at
approximately 24-h intervals after transfection for the number of days indicated in
each experiment. Custom-based algorithms for ImageJ and Pipeline Pilot (Accelrys,
San Diego, CA) software were used to track individual neurons based on fluor-
escence intensity of the transfected morphology marker. Survival or time of death
was determined by a loss of morphology marker fluorescence, cell body rounding,
or dissolution. Cox proportional hazards analysis was used to determine differences
in survival among populations. Cumulative hazard plots were generated using
custom-designed algorithms and the survival package within R. Optical pulse-
labeling experiments were performed as follows: neurons were co-transfected with
photoswitchable fluorescent protein plasmids (Dendra2 or Dendra2-LC3; HTT-
mEos2) and potential modifier or control plasmids. Approximately 24–48 h after
transfection, neurons are pulsed with a 405-nm light for 4 s to photoconvert a
proportion of the photoswitchable protein from green to red. Images are captured
approximately every 4 h in green and red fluorescence channels for 3–5 time
points, and then approximately every 24 h thereafter. Fluorescence in the red
channel represents only the protein that existed at the time of photoconversion,
while fluorescence in the green channel represents previously and newly synthe-
sized protein. Intensity of the photoconverted protein in individual neurons is
measured at each 4-h time point with the analysis software described above and
used to calculate the protein half-life33,34.
Super-resolution microscopy. Cells were seeded on glass-bottom gridded dishes
(MatTek) and imaged with a Nikon N-SIM. Raw 3D-SIM images were acquired (15
images representing five phases and three rotations at each focal plane) typically
using 200-ms exposure and Plan Apo IR ×60/1.27 objective. Images were recon-
structed using NIS-Elements 4.12.
Immunofluorescence. At 48–72 h after transfection, neurons were treated with
ammonium chloride (50 mM) or Bafilomycin A (25 nM) for 3–4 h and subjected to
live-cell or fixed-cell imaging. Fixation occurred at room temperature with cold 4%
paraformaldehyde for 10 min. Protein blocking was done with 5% goat serum/
0.01% Triton in phosphate-buffered saline for 1 h at room temperature. Cells were
incubated overnight with polyclonal rabbit anti-p62 (Abcam) and incubated with a
secondary antibody Alexa-647 (1:500) for 1 h at room temperature.
Protein expression immunoblotting and immunoprecipitation. Protein lysates
were prepared by standard methods. Briefly, cells were lysed in RIPA buffer (150
mM NaCl, 1% NP-40, 0.1% sodium dodecyl sulfate, 0.5% sodium deoxycholate,
and 50 mM Tris, pH 7.4) supplemented with protease inhibitor cocktail (Roche).
Bradford reagent or BCA protein assay kit was used to determine protein con-
centrations. Lysates were separated by SDS-polyacrylamide gel electrophoresis and
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transferred to nitrocellulose for western analysis. Immunoprecipitations were
performed with protein G Dynabeads according to the manufacturer’s instructions
(Life Technologies). Anti-Usp12 (Origene), anti-Usp46 (Atlas Antibodies), anti-
GFP (Millipore), anti-tubulin (Abcam), anti-Optn (Bethyl labs), and anti-p62
(Progen) antibodies were used at 1:1000–1:5000 dilution. Fluorescent conjugated
secondary antibodies (Li-Cor) were used at 1:10 000–20 000 dilutions. Signal was
detected by scanning membranes with Li-Cor Odyssey CLx system. Quantification
was performed with ImageStudio software (Li-Cor). Full immunoblots are showed
in Supplementary Fig. 11.
Lentivirus generation and EM. HEK293T cells (Life Technologies) were trans-
fected with Usp12-FUGW2 or GFP-FUGW, and delta8.9 and VSVG plasmids to
generate lentivirus. Supernatant was collected 48–96 h after transfection and con-
centrated by PEG precipitation and centrifugation. Lentivirus was titered with
Lenti-X p24 Rapid Titer Kit (Clontech). Primary rodent neuronal cultures trans-
duced with GFP or Usp12 lentivirus for approximately 5 days, were fixed in 2%
glutaraldehyde, 1% paraformaldehyde in 0.1 M sodium cacodylate buffer, pH 7.4,
post-fixed in 2% osmium tetroxide in the same buffer, en block stained with 2%
aqueous uranyl acetate, dehydrated in acetone, infiltrated, and embedded in LX-
112 resin (Ladd Research Industries). Samples were ultrathin-sectioned on a
Reichert Ultracut S ultramicrotome and counterstained with 0.8% lead citrate.
Grids were examined on a JEOL JEM-1230 transmission electron microscope
(JEOL USA, Peabody, MA) and photographed with the Gatan Ultrascan 1000
digital camera (Gatan, Warrendale, PA).
Bioinformatics and statistical analysis. Protein interaction network maps were
generated with the open source software for network visualization, Cytoscape
(version 3.2.1)52. Protein interactions were imported from BIOGRID, a general
repository for interaction datasets53. Networks for HTT, Usp12, Wdr20, and Optn
were visualized and merged to generate the interaction map, with each of these
proteins representing a node or hub in the network. Interactors were filtered to
include only first neighbors of each of the nodes. Protein IDs (abbreviations) for
each interactor are indicated on the network map in the Supplementary Fig. 7. Cox
proportional hazards analysis was used for survival experiments. For half-life
experiments, half-life values were determined by first-order exponential decay
modeling, mean half-lives were compared by Mann-Whitney Wilcoxon test, and
distributions compared with two-sided Kolmogorov-Smirnov test. Mean protein
expression levels from western blot and EM analysis were compared with Student’s
t-test.
Quantitative polymerase chain reaction analyses from mammalian cells. Total
RNA of cells was prepared with RNeasy Micro Kit (Qiagen) in accordance with the
manufacturer’s instructions. Single-stranded complementary DNA was produced
by reverse transcription using 1 µg of DNA-free RNA in a 20-µl reaction High-
Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Quantitative
polymerase chain reaction (qPCR) was performed using the TaqMan probe-based
system (Applied Biosystems) on the ABI 7900HT as per the manufacturer’s
instructions (Applied Biosystems; Wdr20 Rn01430046_m1; Wdr48
Rn01447049_m1; beta-Actin Rn00667869; Usp12 Rn01774390_g1).
qPCR analyses from Drosophila samples. For qPCR quantification of relative
Usp12 expression in Drosophila, CG7023 RNAi and UAS CG7023 overexpression
lines were crossed to the actin-GAL4 driver. Newly emerged adult offspring (day 0)
were snap-frozen in liquid nitrogen and stored at −80 °C before RNA extraction.
Six biological replicates consisting of 15 whole fly bodies each were used for the
analysis groups. RNA was extracted using TRIzol reagent (Ambion) according to
the manufacturer’s instructions. RNA was treated with TURBO DNase (Ambion)
to remove any traces of genomic DNA, before synthesis of cDNA using the
QuantiTect Reverse Transcription Kit (Qiagen). CG7023 and rp49 primer
sequences were obtained through Fly PrimerBank54. Primers were tested for spe-
cificity and optimum annealing temperature using temperature-gradient PCR prior
to qPCR, and melt curve analysis was performed on qPCR products. qPCR reac-
tions were performed on a LightCycler 480 system (Roche) using Maxima SYBR
Green master mix (ThermoFisher Scientific). Total reaction volume was 10 µl, with
forward and reverse primer concentrations of 330 nM. Four technical replicates
were used for each sample and a control reaction in which no reverse transcription
was carried out was also included. Crossing points (Cp) were determined by the
second derivative method using LightCycler 480 Software (Roche). For relative
expression quantification, raw fluorescence data of technical replicates were aver-
aged for each sample. The amplification efficiency of each reaction was calculated
using the qpcR package in R Studio55 by fitting sigmoidal curves to the raw
fluorescence data, using the pcrbatch function. The relative expression of CG7023
in overexpression and RNAi lines was normalized to each corresponding UAS
control line, calculated using the ratiobatch function with the Cp value of rp49 used
as an internal control for each sample. Statistical significance of relative expression
levels was tested using a pairwise-reallocation test based upon that used by REST
software56, where Cp and efficiency values were permutated within control and
treatment groups.
Data availability. The data that support the findings of this study are available
from the corresponding author upon reasonable request.
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